Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose post-transplant cyclophosphamide plus very low-dose ATG-F for GVHD prophylaxis after HLA-matched sibling peripheral blood stem cell transplantation
ChiCTR2400092045Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide, anti-T-lymphocyte globulin (rabbit), cyclosporine, tacrolimus and methotrexate in graft-versus-host disease (GVHD) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Incidence of grade II to IV acute graft-versus-host disease. Started Nov 2024; status: recruiting.
02
Drugs
cyclophosphamideanti-T-lymphocyte globulin (rabbit)cyclosporinetacrolimusmethotrexate
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2400092045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092045.